Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837692 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02837692 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 140 participants.
The verdict
NCT02837692, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in elderly non-Asian adults compared with weight- and gender-matched young healthy non-Asian adults and to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in healthy Japanese adults.
Interventions
- DRUG JNJ-42847922 10 milligram (mg)
- DRUG JNJ-42847922 20 mg
- DRUG JNJ-42847922 40 mg
- DRUG JNJ-42847922 60 or 80 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2017-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02837692
The ClinicalTrials.gov registry entry for NCT02837692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which JNJ-42847922 10 milligram (mg) is the first listed.
NCT02837692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02837692 about?
NCT02837692 is a clinical study titled "A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults". The purpose of this study is to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in elderly non-Asian adults compared with weight- and gender-matched young healthy non-Asian adults and to assess the pharmacokinetics of single-dose evening administration of JNJ-428479...
What is the current status of trial NCT02837692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2016-06-08. Estimated completion is 2017-09-11.
What interventions are being tested in trial NCT02837692?
The interventions under investigation include: JNJ-42847922 10 milligram (mg) (DRUG), JNJ-42847922 20 mg (DRUG), JNJ-42847922 40 mg (DRUG), JNJ-42847922 60 or 80 mg (DRUG).
Who is sponsoring clinical trial NCT02837692?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.